Skip to main content

Emergent BioSolutions Gets $199M HHS Funds to Mature Anthrax Vaccine Candidate

By October 6, 2016News
emergent-biosolution-logo

emergent-biosolution-logo

The Department of Health and Human Services has awarded Emergent BioSolutions a five-year, $198.7 million contract to further mature the development of an anthrax vaccine in preparation for a Food and Drug Administration license.

The HHS office of the assistant secretary for preparedness and response’s Biomedical Advanced Research and Development Authority and Emergent BioSolutions will work to validate the effect of the vaccine candidate NuThrax and verify its safety as part of the contract, HHS said Friday.

{iframe}https://www.govconwire.com/2016/10/emergent-biosolutions-gets-199m-hhs-funds-to-mature-anthrax-vaccine-candidate/{/iframe}

Leave a Reply

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.